3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
Azacitidine
10
venetoclax
7
decitabine and cedazuridine drug combination
6
Tacrolimus
4
Decitabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
Injections
3
Cytarabine
3
Busulfan
3
Biopsy
3
ruxolitinib
2
itacitinib
2
fludarabine
2
Whole-Body Irradiation
2
Vorinostat
2
Specimen Handling
2
Sirolimus
2
Mycophenolic Acid
2
Lenalidomide
2
CPX-351
2
veliparib
1
tagraxofusp
1
spartalizumab
1
seclidemstat
1
sabatolimab
1
quizartinib
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, Myelomonocytic, Chronic
×
bexmarilimab
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled